

1

2 **Lack of protective effect of chloroquine derivatives on COVID-19**
3 **disease in a Spanish sample of chronically treated patients.**

4 **Marina Laplana¹, Oriol Yuguero^{2,3}, Joan Fibla^{3,4,*}**

5 ¹ Departament de Ciència Animal, Universitat de Lleida, Lleida, Spain

6 ² Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain

7 ³ Institut de Recerca Biomedica de Lleida, Lleida, Spain

8 ⁴ Unitat de Genètica Humana, Departament de Ciències Mèdiques Bàsiques, Lleida, Spain

9

10 M. Laplana, PhD: marina.laplana@udl.cat. ORCID: 0000-0002-2548-0704

11 O. Yuguero, PhD, MD: oriolyuguero@gencat.cat. ORCID: 0000-0002-3433-8005

12 J. Fibla, PhD : joan.fibla@udl.cat. ORCID: 0000-0002-3255-2227

13

14

15 *** Corresponding author:**

16 E-mail: joan.fibla@udl.cat (JF)

17

18 **Running heads:** No prophylactic effect of hydroxychloroquine against COVID-19 disease

19

20 Abstract

21 **Background:** The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We
22 evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals.

23 **Methods:** We performed a survey addressed to patients regularly taking chloroquine and its
24 derivatives for the control of their autoimmune diseases. The survey was distributed with special
25 attention to Spanish patient associations centred on autoimmune diseases and rheumatology and to
26 the general population. A sample of untreated subjects was matched to the treated group according to
27 sex, age range and incidence region. COVID-19 disease prevalence was compared between treated
28 and untreated-matched control sample.

29 **Results:** A total of 319 surveys of patients regularly taking chloroquine and its derivatives were
30 recovered for further analysis. The prevalence of declared COVID-19 status in the treated group was
31 5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A community
32 exposition to COVID-19 was associated with a greater prevalence of COVID-19 in both, treated
33 (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value=0.027).

34 **Conclusion:** We did not find differences of reported COVID-19 cases between treated and untreated
35 groups, indicating a lack of protection by regular administration of chloroquine and its derivative
36 drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly take
37 chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same protection
38 measures as the general population.

39 **Keywords:** chloroquine, COVID-19 prevalence, hydroxychloroquine, prophylaxis, SARS-CoV-2

40

41 **Introduction**

42 The search for an effective treatment against SARS-CoV-2 infection has emerged as a worldwide
43 priority. A promising strategy to fight the virus causing the newest pandemic is the identification of
44 already available drugs active against other diseases that can be effective also against this new
45 SARS-CoV-2 infection [1].

46 We present here an evaluation of the potential protective effect of chloroquine and its derived drugs
47 on the prevalence of COVID-19 in patients undergoing an active treatment with these drugs.

48 Chloroquine and its derived drugs such as hydroxychloroquine have shown *in vitro* and *in vivo*
49 effectiveness against viral infections such as SARS [2], influenza A H5N1, and Zika. Chloroquine is
50 believed to interfere with both the entry and exit of viruses from cells hosts, as well as in the
51 manifestation of acute respiratory syndrome. The virus enters the cells through binding to the
52 angiotensin-converting enzyme 2 (ACE2). Chloroquine can reduce ACE2 glycosylation, thereby
53 preventing viruses from effectively binding to cells [3]. On the other hand, chloroquine accumulates
54 in lysosomes, increasing the endosome pH levels which interferes with the viral particle release
55 process [4]. In addition, chloroquine could block the production of proinflammatory cytokines, thus
56 preventing the pathway that subsequently leads to acute respiratory syndrome [5]. Two recent clinical
57 trials have presented inconclusive evidence on the effectiveness of chloroquine treatment in COVID-
58 19 disease in Chinese [6] and French [7] populations. Both studies have supported the use of
59 chloroquine or chloroquine derivatives against COVID-19, however, the design and conclusions of
60 both studies have been questioned [8].

61 Chloroquine and its derivatives such as chloroquine phosphate or hydroxychloroquine are commonly
62 used in the treatment of autoimmune diseases. Not without serious side effects, the use of these drugs

63 under medical prescription is widely spread. It has been proposed hydroxychloroquine as a
64 prophylaxis treatment against SARS-CoV-2 infection for exposed caregivers [9]. Our hypothesis is
65 that if chloroquine treatment is effective against SARS-CoV-2 infection, those patients following an
66 active chloroquine or derivative drug treatment would be protected against the infection or against
67 COVID-19 adverse effects. Thus, our study aims to test this hypothesis by evaluating the incidence
68 of COVID-19 disease in the population according to chloroquine treatment subgroups through a
69 survey.

70 **Material and methods**

71 **Survey design and data collection**

72 A survey was designed to be conducted electronically via smartphone or personal computer, and
73 therefore it was also designed to ensure accessibility and simplicity to facilitate its completion.
74 Information about the project and a link to the URL of the survey were disseminated in the press and
75 via social media and email, with special attention to Spanish patient associations centered on
76 autoimmune diseases and rheumatology. The survey included demographic questions about gender,
77 age range, and province of residence, as well as questions pertaining to health-status outcomes such
78 as treatment, COVID-19 diagnosis and symptoms due to COVID-19 infection. In addition, questions
79 about infection diagnosis and symptoms in close relatives and friends were also included. Because
80 the first cases of COVID-19 were reported in Spain in March 2020, our survey collects cases that
81 occurred between March and May 2020.

82 Individuals of any age above legal age (18 years old) with residence in Spain were eligible for
83 inclusion in the study. Individuals undergoing a stable chloroquine or derived drug treatment before

84 the COVID-19 pandemic were classified as treated (treated group) while individuals without
85 treatment were classified as untreated (untreated group).

86 The Clinical Research Ethics Committee of the Hospital Universitari Arnau de Vilanova in Lleida
87 approved the study (Ref: CEIC-2257).

88 **Statistical analysis**

89 Statistical analyses were performed with R software (v3.6.0) and IBM SPSS v21 (IBM corporation,
90 NY, USA). Prior to the analysis, reported provinces of residence in Spain were grouped according to
91 COVID-19 incidence as stated in June 1 by the Spanish Ministry of Health [10] as follows: Incidence
92 region 1 (incidence<200/100,000 inhabitants) that includes Andalucía, Canarias, Ceuta, Illes Balears,
93 Melilla and Región de Murcia; Incidence region 2 (incidence 200-500/100,000 inhabitants) that
94 includes Aragón, Cantabria, Comunidad Valenciana, Extremadura, Galicia and Principado de
95 Asturias; Incidence region 3 (incidence 500-1,000/100,000 inhabitants) that includes Castilla y León,
96 Castilla-La Mancha, Catalunya, Euskadi and Navarra; and Incidence region 4
97 (incidence>1,000/100,000 inhabitants) that includes Comunidad de Madrid and La Rioja. Age
98 categories were assigned according to the following age ranges: 18-50, 51-65 and >65 years old.
99 Data on symptoms related to COVID-19 infection were collected and used to assign individuals as
100 suspected COVID-19 cases when reporting loss of taste or smell and/or three or more COVID-19
101 associated symptoms [11].

102 A sample of untreated subjects was matched to the treated group according to sex, age range and
103 incidence region with e1071 R package. The matching process was repeated using a bootstrap
104 strategy and re-sampling of the untreated-matched dataset was repeated 1,000 times to obtain the
105 distribution and mean values of the descriptive statistics such as age range, gender, incidence region

106 and declared COVID-19 prevalence. Comparisons between groups were performed by Fisher exact
107 test. P-value<0.05 was considered statistically significant.

108 **Results**

109 Overall, 2295 individuals completed the surveys between May and June 2020. From these, data
110 collection was complete, with all key data for the study, for 2161 individuals (94.2%). Of these
111 completed surveys, 11 entries did not meet eligibility criteria and were excluded from the analysis.
112 The final number of completed surveys used for the study was 2150. Among them, 319 (14.8%) were
113 from patients following an active chloroquine or derived drug treatment and have been included in
114 the treatment group, and 1831 (85.2%) have been included in the untreated group and serves as the
115 source to obtain the untreated-matched subgroups. We note that 94% of the treatment group
116 individuals were following a hydroxychloroquine treatment.

117 The main descriptive characteristics of both treated (n=319) and untreated-matched (n=319)
118 subgroups, arranged according to their declared COVID-19 status, are reported in Table 1.
119 Distribution of declared COVID-19 status did not differ significantly within age group, gender and
120 incidence region (Table 1). In contrast, having a community exposition (defined as those individuals
121 declaring a COVID-19 positive case in a close family member or flatmate) was associated with a
122 greater prevalence of COVID-19 disease when compared with non-exposed individuals in both
123 treated (17.0%, 95%CI 12.9%-21.1% vs. 3.2%, 95%CI 1.3%-5.2%; p-value<0.001) and untreated
124 subgroups (13.4%, 95%CI 9.6%-17.1% vs. 1.1%, 95%CI 0%-2.2%; p-value=0.027) (Table 1 and Fig
125 1).

126

127

Table 1 - Demographic characteristics of persons taking chloroquine or derivatives (treated) and matched control sample (untreated) according to their declared COVID-19 status

| | Treated (n=319) | | | | Untreated (n ^a =319) | | | |
|---------------------------------------|-----------------|--------------|--------|---------|---------------------------------|--------------|--------|---------|
| | COVID-19 (+) | COVID-19 (-) | Totals | P-value | COVID-19 (+) | COVID-19 (-) | Totals | P-value |
| Age range, n (%) | | | | | | | | |
| 18-50 | 9 (4.7) | 182 (95.3) | 191 | 0.433 | 6.7 (3.5) | 185.4 (96.5) | 192.2 | 0.999 |
| 51-65 | 8 (7.1) | 105 (92.9) | 113 | | 3.9 (3.5) | 107.5 (96.5) | 111.3 | |
| > 65 | 0 (0.0) | 15 (100.0) | 15 | | 0.3 (2.1) | 15.2 (97.9) | 15.5 | |
| Total | 17 (5.3) | 302 (94.7) | 319 | | 10.9 (3.4) | 308.1 (96.6) | 319 | |
| Sex, n (%) | | | | | | | | |
| Male | 1 (4.8) | 20 (95.2) | 21 | 0.905 | 1.1 (5.0) | 20.2 (95.0) | 21.2 | 0.973 |
| Female | 16 (5.4) | 282 (94.6) | 298 | | 9.8 (3.3) | 287.9 (96.7) | 297.8 | |
| Total | 17 (5.3) | 302 (94.7) | 319 | | 10.9 (3.4) | 308.1 (96.6) | 319 | |
| Incidence region ^b , n (%) | | | | | | | | |
| R1 | 1 (2.4) | 40 (97.6) | 41 | 0.420 | 0.0 (0.0) | 41.1 (100.0) | 41.1 | 0.275 |
| R2 | 1 (2.8) | 35 (97.2) | 36 | | 1.0 (3.4) | 28.7 (96.6) | 29.7 | |
| R3 | 11 (5.4) | 193 (94.6) | 204 | | 6.1 (2.7) | 218.8 (97.3) | 225.0 | |
| R4 | 4 (11.4) | 31 (88.6) | 35 | | 3.2 (15.9) | 17.0 (84.1) | 20.2 | |
| Unknown | 0 (0.0) | 3 (100.0) | 3 | | 0.5 (17.3) | 2.5 (82.7) | 3.0 | |
| Total | 17 (5.3) | 302 (94.7) | 319 | | 10.9 (3.4) | 308.1 (96.6) | 319 | |
| Community exposition, n (%) | | | | | | | | |
| Exposed ^c | 8 (17.0) | 39 (83.0) | 47 | <0.001 | 8.2 (13.3) | 53.3 (86.7) | 61.5 | 0.027 |
| Unexposed | 7 (3.2) | 210 (96.8) | 217 | | 2.2 (1.1) | 204.4 (98.9) | 206.6 | |
| Unknown | 2 (3.6) | 53 (96.4) | 55 | | 0.5 (1.0) | 50.4 (99.0) | 50.9 | |
| Total | 17 (5.3) | 302 (94.7) | 319 | | 10.9 (3.4) | 308.1 (96.6) | 319 | |

COVID-19: disease caused by SARS-CoV-2 infection.

^a Mean after 1000 replicates of matched untreated control samples.

^b Regions grouped by incidence of COVID-19. IR1 (incidence <200/100,000 inhabitants) that includes Andalucía, Canarias, Ceuta, Illes Balears, Melilla and Región de Murcia; IR2 (incidence 200-500/100,000 inhabitants) that includes Aragón, Cantabria, Comunidad Valenciana, Extremadura, Galicia and Principado de Asturias; IR3 (incidence 500-1,000/100,000 inhabitants) that includes Castilla y León, Castilla-La Mancha, Catalunya, Euskadi and Navarra; and IR4 (incidence >1,000/100,000 inhabitants) that includes Comunidad de Madrid and La Rioja.

^c Exposed were those individuals declaring a COVID-19 positive case in a close family member or flatmate.

128

129 The prevalence of declared COVID-19 status in the treated group was 5.3% (95%CI 2.9-7.8) and the
 130 mean prevalence among the untreated-matched groups was 3.4% (95%CI 1.4-5.4). Furthermore, the
 131 prevalence of suspected COVID-19 patients in treated subjects was of 18.8% (95%CI 14.5-23.1) and
 132 the mean prevalence among the untreated-matched groups was 15.7% (95%CI 11.7-19.7). These
 133 figures are nearly similar to those recently found in the study of the seroprevalence of IgG antibodies

134 against SARS-CoV-2 in the Spanish population showing an estimated prevalence of 5% (95%CI
135 4.7%-5.4%), and a prevalence of suspected COVID-19 cases of nearly 20%.[11]

136 **Discussion**

137 Our results show no differences in COVID-19 prevalence among untreated and chronically treated
138 individuals with chloroquine or derivative drugs. Independently of the exposure, both groups showed
139 the same prevalence of COVID-19 disease or suspected COVID-19 disease according to symptoms.
140 We must note that we found a clear association between the COVID-19 disease prevalence and
141 exposure to a close family member or flatmate positive for COVID-19 in both, treated and untreated
142 subjects, that points to a lack of any protective effect on SARS-CoV-2 infection attributable to
143 chronic treatment with chloroquine or derivative drugs.

144 We should mention some limitations of our study such as a limited power to detect small changes in
145 prevalence between treatment groups. However, the design of this study addressed the need to collect
146 and analyse data within a particularly short period of time due to the rapid onset and progression of
147 the pandemic, as well as the urgency of identifying and evaluating rapidly possible therapies, thus
148 partially compensating the reduced sample size. The prevalence of COVID-19 found in our study is
149 similar to the seroprevalence of IgG antibodies against SARS-CoV-2 in the Spanish population [11],
150 which is higher than the reported COVID-19 prevalence in the general population based on RNA's
151 virus detection [10]. This difference could be attributed to self-reported disease and the diagnosis of
152 COVID-19 by medical practitioners, which in many cases does not involve results of diagnostic tests
153 due to the lack of such tests. Finally, we could not eliminate completely the possibility of some bias
154 due to the intrinsic condition of the individuals within the treatment group that are undergoing
155 chloroquine or derivative drug treatment due to other diseases that alter their health status and may
156 have different comorbidities. However, our results are in line with a recent study conducting a

157 randomized trial that reported no effect of hydroxychloroquine when used as a post exposure
158 prophylaxis for COVID-19 [12].

159 All these data together point towards a lack of a protective effect of chloroquine or derivative drugs
160 as a prophylaxis for COVID-19, including prophylactic treatment before and after exposure. Of
161 relevance, data indicates that people that regularly take chloroquine derivatives are exposed to
162 SARS-CoV-2 infection and must take the same protection measures as the general population. These
163 data should be considered in the prevention and treatment protocols made by health policymakers for
164 the management of the disease in new outbreaks.

165 **Acknowledgments**

166 This study and the research behind it would not have been possible without the selfless contribution
167 of all the people who participated and that took time to respond the survey. We would like to thank
168 Dr. Serafi (Tapi) Piñol for his valuable comments and suggestions.

169 **Author Contributions**

170 JF created the online survey, conceived and design the study. ML and JF were responsible for data
171 analysis. All authors were involved in the development of the survey, contributed to the writing of
172 the manuscript and approved the final draft

173 **Conflict of Interest**

174 The authors declare that the research was conducted in the absence of any commercial or financial
175 relationships that could be construed as a potential conflict of interest.

176 **Funding**

177 This research did not receive any specific grant from funding agencies in the public, commercial, or
178 not-for-profit sectors.

179

180 **References**

- 181 1. Thangaraju P, Gurunthalingam MP, Venkatesan S, Thangaraju E. COVID-19: Wait for a
182 novel drug or act with the age old drug - Do we have a choice? *J Infect Public Health*.
183 2020 Jun;13(6):899–900.
- 184 2. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute
185 respiratory syndrome coronavirus by chloroquine. *Biochem Biophys Res Commun*. 2004
186 Oct 8;323(1):264–8.
- 187 3. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of
188 chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob*
189 *Agents*. 2020 Mar 12;:105938.
- 190 4. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising
191 strategy for the treatment of emerging viral diseases. *Pharmacol Res Perspect*. John
192 Wiley & Sons, Ltd; 2017 Feb;5(1):e00293.
- 193 5. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral
194 infections: an old drug against today's diseases? *Lancet Infect Dis*. 2003 Nov;3(11):722–
195 7.
- 196 6. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent
197 efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci*
198 *Trends*. International Research and Cooperation Association for Bio & Socio-Sciences
199 *Advancement*; 2020 Mar 16;14(1):72–3.
- 200 7. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.

- 201 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-
202 label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020 Mar 20;:105949.
- 203 8. Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res*. 2020
204 May;177:104762.
- 205 9. Tahiri Joutei Hassani R, Bennis A. Hydroxychloroquine as antiviral prophylaxis for
206 exposed caregivers to Covid-19: An urgent appraisal is needed. *J Infect Public Health*.
207 2020 Jun;13(6):865–7.
- 208 10. Actualización no 123. Enfermedad por el coronavirus (COVID-19). 01.06.2020. Centro
209 de Coordinación de Alertas y Emergencias Sanitarias. Dirección general de salud pública,
210 calidad e innovación; Jun 1, 2020 pp. 1–12. Available at:
211 [https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_123_COVID-19.pdf)
212 [China/documentos/Actualizacion_123_COVID-19.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_123_COVID-19.pdf)
213
- 214 11. Estudio ENE-COVID19: primera ronda estudio nacional de sero-epidemiología de la
215 infección por SARS-COV-2 en España. Informe preliminar 13 de mayo de 2020. 2020.
216 pp. 1–18. Available at:
217 https://portalcne.isciii.es/enecovid19/documentos/ene_covid19_inf_pre.pdf
218
- 219 12. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al.
220 A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
221 *N Engl J Med*. 2020 Jun 3;:NEJMoa2016638–9.
- 222




Figure 1.- Percentage of declared COVID-19 cases according to treatment status and community exposition. Treated group refers to patients regularly taking chloroquine and its derivatives. Exposed are those individuals declaring a COVID-19 positive case in a close family member or flatmate. Error bars depict the 95% confidence interval.